Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC-Reference-Cited by-同舟云学术

Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

Published:2023-05 Issue:5 Volume:18 Page:587-598
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dercle Laurent,Fronheiser Matthew,Rizvi Naiyer A.,Hellmann Matthew D.,Maier Sabine,Hayes Wendy,Yang Hao,Guo Pingzhen,Fojo Tito,Schwartz Lawrence H.,Zhao Binsheng,Leung David K.

Funder

Bristol-Myers Squibb

National Institutes of Health

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization;Yamamoto;Radiology,2014

2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study;Sun;Lancet Oncol,2018

3. Radiomics signature: a potential biomarker for the prediction of disease-free survival in early-stage (I or II) non-small cell lung cancer;Huang;Radiology,2016

4. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics;Dercle;Clin Cancer Res,2020

5. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group;Lung Cancer;2024-07

2. Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study;Academic Radiology;2024-07

3. The Causal Effect of Gut Microbiota and Plasma Metabolome on Lung Cancer and the Heterogeneity across Subtypes: A Mendelian Randomization Study;Journal of Personalized Medicine;2024-04-25

4. Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity;Bioorganic Chemistry;2024-01

5. A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-12